' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID


Gewähltes Keyword: interferon-beta

High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
Hegen, H; Guger, M; Harrer, A; Hoelzl, M; Kraus, J; Skrobal, A; Schautzer, F; Schmidegg, S; Schocke, M; Deisenhammer, F;
Mult Scler Relat Disord. 2014; 3(2):220-226
Originalarbeiten (Zeitschrift)
Serum from interferon-beta-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro
Muller, M; Frese, A; Nassenstein, I; Hoppen, M; Marziniak, M; Ringelstein, EB; Kim, KS; Schabitz, WR; Kraus, J
MULT SCLER J. 2012; 18(2): 236-239.
Originalarbeiten (Zeitschrift)
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
Sellner, J; Weber, MS; Vollmar, P; Mattle, HP; Hemmer, B; Stüve, O;
CNS Neurosci Ther. 2010; 16(6): 362-373.
Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Gneiss, C; Koudouovoh-Tripp, PM; Ropele, S; Gotwald, T; Ehling, R; Lutterotti, A; Aichner, F; Ladurner, G; Eggers, C; Schautzer, F; Künz, B; Millonig, A; Aspeck, E; Reindl, M; Berger, T; Fazekas, F; Deisenhammer, F;
MULT SCLER. 2009; 15(12): 1481-1488.
Originalarbeiten (Zeitschrift)
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Kraus, J; Voigt, K; Schuller, AM; Scholz, M; Kim, KS; Schilling, M; Schäbitz, WR; Oschmann, P; Engelhardt, B;
MULT SCLER. 2008; 14(6): 843-852.
Originalarbeiten (Zeitschrift)
Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.
Sellner, J; Greeve, I; Findling, O; Grandgirard, D; Leib, SL; Mattle, HP;
Clin Exp Immunol. 2008; 152(2):280-284
Originalarbeiten (Zeitschrift)
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.
Sellner, J; Greeve, I; Findling, O; Kamm, CP; Minten, C; Engelhardt, B; Grandgirard, D; Leib, SL; Mattle, HP;
Neurochem Int. 2008; 53(1-2):17-21
Originalarbeiten (Zeitschrift)
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Sellner, J; Greeve, I; Mattle, HP;
Mult Scler. 2008; 14(7):981-984
Originalarbeiten (Zeitschrift)
New therapeutics targets in chronic viral cardiomyopathy.
Poller, W; Fechner, H; Kühl, U; Pauschinger, M; Schultheiss, HP;
Ernst Schering Res Found Workshop. 2006; 287-303
CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis, N; Kraus, J; Bauer, R; Engelhardt, B; Bregenzer, T; Kuehne, BS; Tofighi, J; Laske, C; Stolz, E; Blaes, F; Voigt, K; Traupe, H; Kaps, M; Oschmann, P;
ACTA NEUROL SCAND. 2004; 110(6): 377-385.
Originalarbeiten (Zeitschrift)
Interferon-beta(1b) leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis
Kraus, J; Bauer, R; Chatzimanolis, N; Engelhardt, B; Tofighi, J; Bregenzer, T; Kuehne, BS; Stolz, E; Blaes, F; Morgen, K; Traupe, H; Kaps, M; Oschmann, P
J NEUROL. 2004; 251(4): 464-472.
Originalarbeiten (Zeitschrift)
Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy.
Noutsias, M; Pauschinger, M; Poller, WC; Schultheiss, HP; Kühl, U;
Heart Fail Monit. 2003; 3(4):127-135